Peptides whose uptake in cells is controllable

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9682151
APP PUB NO 20120134931A1
SERIAL NO

13384591

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Disclosed herein, in certain embodiments, is a selective transport molecule with increased in vivo circulation. In some embodiments, a selective transport molecule disclosed herein has the formula (A-X-B-C)-M, wherein C is a cargo moiety; A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X is a linker; and M is a macromolecular carrier.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

International Classification(s)

Inventor(s)

  • No Inventor to display

Cited Art Landscape

Patent Info (Count) # Cites Year
 
YAZAKI CORPORATION (1)
2013/0176,335 VEHICULAR DISPLAY DEVICE AND VEHICULAR DISPLAY SYSTEM 2 2013
 
Other [Check patent profile for assignment information] (1)
2002/0009,786 Novel nucleic acids and polypeptides 7 2000
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (11)
* 7431915 Peptides whose uptake by cells is controllable 8 2003
2005/0107,583 Peptides whose uptake by cells is controllable 4 2003
* 7985401 Peptides whose uptake by cells is controllable 7 2005
2006/0041,105 Peptides whose uptake by cells is controllable 7 2005
2007/0041,904 Peptides whose uptake by cells is controllable 19 2006
* 8110554 Peptides whose uptake by cells is controllable 5 2008
2012/0134,922 PEPTIDES WHOSE UPTAKE IN CELLS IS CONTROLLABLE 5 2010
* 9072792 Peptides whose uptake by cells is controllable 3 2011
2012/0014,873 PEPTIDES WHOSE UPTAKE BY CELLS IS CONTROLLABLE 2 2011
* 8642561 Peptides whose uptake by cells is controllable 5 2011
2013/0078,188 ACTIVATABLE CELL PENETRATING PEPTIDES WITH QUENCHED FLUOROPHORES 4 2012
 
SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (1)
2011/0160,147 NOVEL DUAL TARGETING ANTITUMORAL CONJUGATES 3 2009
 
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (1)
6306993 Method and composition for enhancing transport across biological membranes 153 1998
 
NEKTAR THERAPEUTICS (1)
2001/0021,763 Soluble, degradable poly (ethylene glycol) derivatives for controllable release of bound molecules into solution 58 2001
 
THE GENERAL HOSPITAL CORPORATION (4)
6083486 Intramolecularly-quenched near infrared fluorescent probes 52 1998
6592847 Intramolecularly-quenched near infrared flourescent probes 37 2000
2004/0241,096 Imaging of enzymatic activity 4 2004
8486373 Intramolecularly-quenched near infrared fluorescent probes 6 2004
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (1)
2005/0069,494 Cyclic peptide and imaging compound compositions and uses for targeted imaging and therapy 4 2004
 
SEATTLE GENETICS, INC. (1)
2012/0148,610 MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS 18 2012
 
BRITISH BIOTECH PHARMACEUTICALS LIMITED (1)
5434073 Fibrinolytic and anti-thrombotic cleavable dimers 14 1992
 
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (1)
2003/0176,335 Surfactant peptide nanostructures, and uses thereof 21 2002
 
BIOGEN IDEC MA INC. (1)
5674980 Fusion protein comprising tat-derived transport moiety 92 1995
 
MONSANTO COMPANY (2)
4466919 Peptide substrates for mammalian collagenase 13 1982
4507389 Determination of collagenase by reacting with peptide substrates 13 1984
 
BIOGEN MA INC. (1)
5747641 Tat-derived transport polypeptide conjugates 104 1995
 
Washington University School of Medicine (1)
6348185 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy 60 1999
 
GEORGIA TECH RESEARCH CORPORATION (1)
2009/0004,118 Multifunctional Nanoparticle Conjugates And Their Use 36 2005
 
BRACCO RESEARCH S.A. (1)
5910300 Amphiphilic linkers for coupling administrable diagnostically or physiologically active agents and bioselective targeting compounds 18 1996
 
GE HEALTHCARE AS (1)
2004/0009,122 Contrast agents 22 2003
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

  • No Forward Cites to Display

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Dec 20, 2020
7.5 Year Payment $3600.00 $1800.00 $900.00 Dec 20, 2024
11.5 Year Payment $7400.00 $3700.00 $1850.00 Dec 20, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00